Key result
Perfluorocarbon nanoparticles offer new tools for targeted imaging and therapy across a broad spectrum of cardiovascular diseases, from asymptomatic atherosclerosis to acute myocardial infarction.
Perfluorocarbon nanoparticles offer potential new tools for targeted imaging and therapy across a broad spectrum of cardiovascular diseases.
May support preclinical exploration of perfluorocarbon nanoparticles in cardiovascular disease; leaves open clinical translation and safety.
Nanomedicine promises to enhance the ability of clinicians to address some of the serious challenges responsible for cardiovascular mortality, morbidity and numerous societal consequences. Targeted imaging and therapy applications with perfluorocarbon nanoparticles are relevant to a broad spectrum of cardiovascular diseases, ranging from asymptomatic atherosclerotic disease to acute myocardial infarction or stroke. As illustrated in this article, perfluorocarbon nanoparticles offer new tools to recognize and characterize pathology, to identify and segment high-risk patients and to treat chronic and acute disease.
No takes yet. Share an insight, caveat, or question.
Lanza et al. (2006) conducted a review in Cardiovascular disease. Perfluorocarbon nanoparticles was evaluated. Perfluorocarbon nanoparticles offer new tools for targeted imaging and therapy across a broad spectrum of cardiovascular diseases, from asymptomatic atherosclerosis to acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: